EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting

SHANGHAI--(BUSINESS WIRE)-- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, California, from November 3-5. This poster presentation will feature initial safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data from the Phase I dose escalation study in relapsed or refractory multiple myeloma (NCT04735575; CTR20212633). The presentation details are as follows:

Title: A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody EMB06 in Relapsed or Refractory Multiple Myeloma
Abstract number: 1528

“We are very pleased to share the EMB-06 data as a late-breaker at the SITC Annual Meeting. This data will provide the first clinical proof-of-concept that EpimAb’s differentiated bispecific platform and proprietary CD3 panel can be used to effectively target tumor associated antigens while lowering the risk of cytokine release and neurotoxicity,” Dr. Chengbin Wu, Founder and CEO of EpimAb commented. “With multiple T cell engagers in our clinical and pre-clinical pipeline, EpimAb is looking forward to realizing the promising potential of this modality and to creating novel therapies for diseases with significant unmet need.”

About EMB-06

EMB-06 is a novel 2+2 BCMA×CD3 T-cell engaging bispecific antibody discovered using EpimAb’s proprietary CD3 panel and bispecific platforms. Importantly, this molecule has demonstrated lower levels of cytokine release in preclinical and clinical studies. EMB-06 is currently being studied in a Phase I/II trial in relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).

About EpimAb Biotherapeutics Inc

EpimAb Biotherapeutics Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit: www.epimab.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031183230/en/